Literature DB >> 3320747

A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia.

L B Mitchell1, H J Duff, D E Manyari, D G Wyse.   

Abstract

There is controversy over whether therapy to prevent ventricular tachyarrhythmias should be selected noninvasively (by trying drugs and monitoring the patient electrocardiographically) or invasively (by selecting a drug that prevents induction of the arrhythmia by programmed stimulation). We randomly assigned 57 patients with symptomatic and demonstrable ventricular tachyarrhythmias to therapy selected either noninvasively or invasively. The tachyarrhythmias involved were sustained ventricular tachycardia (35 patients), nonsustained ventricular tachycardia with hypotension (15 patients), and ventricular fibrillation (7 patients). The noninvasive approach sought reduction of ventricular premature beats by more than 80 percent and of couplets by more than 90 percent, with elimination of three or more successive ventricular beats on ambulatory monitoring and exercise testing. The invasive approach sought to prevent the induction of five or more repetitive beats by programmed stimulation. The noninvasive approach required fewer drug trials (3.2 +/- 1.8 [mean +/- SD] vs. 5.5 +/- 2.8, P less than 0.001) and fewer hospital days (20 +/- 15 vs. 33 +/- 24, P = 0.01) and identified a therapy predicted to be effective for more patients than did the invasive approach (29 of 29 vs. 15 of 28, P less than 0.001). When a predicted effective therapy was not found, amiodarone was prescribed despite persisting inducibility of ventricular tachycardia. Patients randomly assigned to the noninvasive approach had more symptomatic recurrences of tachyarrhythmia than those treated by the invasive approach (two-year actuarial probabilities of 0.50 +/- 0.10 vs. 0.20 +/- 0.08, P = 0.02). Similar differences were observed when amiodarone recipients were excluded. There were only three deaths from recurrent ventricular tachyarrhythmias--two in the group whose treatment was selected noninvasively and one in the group whose treatment was selected invasively (not significant). We conclude that therapy selected by the invasive approach prevents recurrences of ventricular tachyarrhythmias better than that selected by the noninvasive approach.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3320747     DOI: 10.1056/NEJM198712313172701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

Review 1.  Changing concepts of electrophysiology testing for ventricular arrhythmias.

Authors:  M Akhtar
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

2.  Sudden Cardiac Death.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  1999-08

3.  Life at a price: the implantable defibrillator.

Authors:  R W Campbell
Journal:  Br Heart J       Date:  1990-09

Review 4.  Determination of antiarrhythmic drug efficacy in the treatment of ventricular arrhythmias.

Authors:  J Morganroth
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 5.  Risk-benefit assessment of antiarrhythmic drugs. An epidemiological perspective.

Authors:  L Friedman; E Schron; S Yusuf
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 6.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

7.  The Treatment of PVCs and Prevention of Sudden Cardiac Death: New findings from the CAST study.

Authors:  S Nattel
Journal:  Can Fam Physician       Date:  1991-01       Impact factor: 3.275

Review 8.  Evaluation and treatment strategies in patients at high risk of sudden death post myocardial infarction.

Authors:  R D Underwood; J Sra; M Akhtar
Journal:  Clin Cardiol       Date:  1997-09       Impact factor: 2.882

Review 9.  When is drug therapy warranted to prevent sudden cardiac death?

Authors:  B N Singh
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 10.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.